脂溢性皮炎

Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91:185-190.

• 全文
• 摘要

Schwartz RA. Superficial fungal infections. Lancet. 2004;364:1173-1182.

• 摘要

Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93:557-561.

• 全文
• 摘要

Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Drugs Dermatol. 2013;12:312-315.

• 摘要

1.  Clark GW, Pope SM, Jaboori KA. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015;91:185-190.

• 全文
• 摘要

2.  Friedmann DP, Mishra V, Batty T. Progressive facial papules in an African-American patient: an atypical presentation of seborrheic dermatitis. J Clin Aesthet Dermatol. 2018;11(7):44-45.

• 全文
• 摘要

3.  Gupta AK, Madzia SE, Batra R. Etiology and management of seborrheic dermatitis. Dermatology (Basel). 2004;208:89-93.

• 摘要

4.  Foley P, Zuo Y, Plunkett A, et al. The frequency of common skin conditions in preschool-aged children in Australia: seborrheic dermatitis and pityriasis capitis (cradle cap). Arch Dermatol. 2003;139:318-322.

• 摘要

5.  Mastrolonardo M, Diaferio A, Vendemiale G, et al. Seborrhoeic dermatitis in the elderly: inferences on the possible role of disability and loss of self-sufficiency. Acta Derm Venereol. 2004;84:285-287.

• 摘要

6.  Kamamoto CSL, Nishikaku AS, Gompertz OF, et al.Cutaneous fungal microbiome: Malassezia yeasts in seborrheic dermatitis scalp in a randomized, comparative and therapeutic trial. Dermatoendocrinol. 2017;9(1):e1361573.

• 全文
• 摘要

7.  Schwartz RA. Superficial fungal infections. Lancet. 2004;364:1173-1182.

• 摘要

8.  Faergemann J. Severe seborrheic dermatitis. J Int Postgrad Med. 1990;2:18-20.

9.  Tollesson A, Frithz A, Berg A, et al.. Essential fatty acids in infantile seborrheic dermatitis. J Am Acad Dermatol. 1993;28:957-961.

• 摘要

10.  Kim GW, Jung HJ, Ko HC, et al. Dermoscopy can be useful in differentiating scalp psoriasis from seborrheic dermatitis. Br J Dermatol. 2011;164:652-656.

• 摘要

11.  Lallas A, Argenziano G, Apalla Z, et al. Dermoscopic patterns of common facial inflammatory skin diseases. J Eur Acad Dermatol Venereol. 2014;28:609-614.

• 摘要

12.  Miller ME, Koblenzer PJ. Leiner's disease and deficiency of C5. J Pediatr. 1972;80:879-880.

• 摘要

13.  Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis. J Am Acad Dermatol. 2007;57:257-264.

• 摘要

14.  Hebert AA. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis. Clin Ther. 2006;28:1972-1982.

• 摘要

15.  Firooz A, Solhpour A, Gorouhi F. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2005;142:1066-1067.

• 摘要

16.  Kastarinen H, Oksanen T, Okokon EO, et al. Topical anti-inflammatory agents for seborrhoeic dermatitis of the face or scalp. Cochrane Database Syst Rev. 2014;(5):CD009446.

• 全文
• 摘要

17.  Shuster S, Meynadier J, Kerl H, et al. Treatment and prophylaxis of seborrheic dermatitis of the scalp with antipityrosporal 1% ciclopirox shampoo. Arch Dermatol. 2005;141:47-52.

• 摘要

18.  Swinyer LJ, Decroix J, Langner, A. Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. Cutis. 2007;79:475-482.

• 摘要

19.  Apasrawirote W, Udompataikul M, Rattanamongkolgul S. Topical antifungal agents for seborrheic dermatitis: Systematic review and meta-analysis. J Med Assoc Thai. 2011;94:756-760.

• 摘要

20.  Schwartz JR, Bacon RA, Shah R, et al. Therapeutic efficacy of anti-dandruff shampoos: a randomized clinical trial comparing products based on potentiated zinc pyrithione and zinc pyrithione/climbazole. Int J Cosmet Sci. 2013;35:381-387.

• 摘要

21.  Buechner SA. Multicenter, double-blind, parallel group study investigating the non-inferiority of efficacy and safety of a 2% miconazole nitrate shampoo in comparison with a 2% ketoconazole shampoo in the treatment of seborrhoeic dermatitis of the scalp. J Dermatolog Treat. 2014;25:226-231.

• 摘要

22.  High WA, Pandya AG. Pilot trial of 1% pimecrolimus cream in the treatment of seborrheic dermatitis in African American adults with associated hypopigmentation. J Am Acad Dermat. 2006;54:1083-1088.

• 摘要

23.  Pierard-Franchimont C, Pierard GE. A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology. 2002;204:344-347.

• 摘要

24.  Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001-1008.

• 摘要

25.  Goldust M, Rezaee E, Rouhani S. Double blind study of sertaconazole 2% cream vs. clotrimazole 1% cream in treatment of seborrheic dermatitis. Ann Parasitol. 2013;59:25-29.

• 全文
• 摘要

26.  Seckin D, Gurbuz O, Akin O. Metronidazole 0.75% gel vs. ketoconazole 2% cream in the treatment of facial seborrheic dermatitis: a randomized, double-blind study. J Eur Acad Dermatol Venereol. 2007;21:345-350.

• 摘要

27.  Cicek D, Kandi B, Bakar S, et al. Pimecrolimus 1% cream, methylprednisolone aceponate 0.1% cream and metronidazole 0.75% gel in the treatment of seborrhoeic dermatitis: a randomized clinical study. J Dermatolog Treat. 2009;20:344-349.

• 摘要

28.  Kim TW, Mun JH, Jwa SW, et al. Proactive treatment of adult facial seborrhoeic dermatitis with 0.1% tacrolimus ointment: randomized, double-blind, vehicle-controlled, multi-centre trial. Acta Derm Venereol. 2013;93:557-561.

• 全文
• 摘要

29.  Groisser D, Bottone EJ, Lebwohl M. Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol. 1989;20:770-773.

• 摘要

30.  Medicines and Healthcare Products Regulatory Agency. Oral ketoconazole: do not prescribe or use for fungal infections—risk of liver injury outweighs benefits. August 2013. https://www.gov.uk/ (last accessed 2 February 2017).

• 全文

31.  European Medicines Agency. European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole. July 2013. http://www.ema.europa.eu/ema/ (last accessed 2 February 2017).

• 全文

32.  US Food and Drug Administration. FDA drug safety communication: FDA limits usage of Nizoral (ketoconazole) oral tablets due to potentially fatal liver injury and risk of drug interactions and adrenal gland problems. July 2013. http://www.fda.gov/ (last accessed 2 February 2017).

• 全文

33.  Paghdal KV, Schwartz RA. Topical tar: back to the future. J Am Acad Dermatol. 2009;61:294-302.

• 摘要

34.  Ang-Tiu CU, Medhrajani CF, Maano CC. Pimecrolimus 1% cream for the treatment of seborrheic dermatitis: A systematic review of randomized controlled trials. Expert Rev Clin Pharmacol. 2012;5:91-97.

• 摘要

35.  Ozden MG, Tekin NS, Ilter N, et al. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. Am J Clin Dermatol. 2010;11:51-54.

• 摘要

36.  Meshkinpour A, Sun J, Weinstein G. An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis. J Am Acad Dermatol. 2003;49:145-147.

• 摘要

37.  Diehl C, Ferrari A. Efficacy of topical 4% Quassia amara gel in facial seborrheic dermatitis:a randomized, double-blind, comparative study. J Drugs Dermatol. 2013;12:312-315.

• 摘要